查看文章

HPV screening and vaccination are complementary preventive options often implemented as separate and non-coordinated public health programs. The HPV-FASTER protocols aim to address this disconnect by combining both strategies with the ultimate purpose of accelerating the reduction of cervical cancer incidence and mortality and making the programs both cost-effective and sustainable.

Results from two phase III trials comparing HPV vaccination against placebo among adult women (aged up to 45 years and 55 years for 4vHPV and 2vHPV vaccines, respectively) 1 1. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105: 28-37. https://doi. org/10.1038/bjc. 2011.185